
Two Cornell engineers set out to recreate lubricin, a slippery glycoprotein that keeps healthy knees, hips and shoulders gliding smoothly against each other for a lifetime. When joints are injured or age, lubricin production drops, friction rises, and cartilage begins to wear away, a process that can lead to osteoarthritis, a disease affecting more than 32 million adults in the United States.
Now, their discovery of a lubricin-inspired polymer has not only led to a start-up co-founded by one of their doctoral students but is also entering two separate first-in-human trials. The team aims to give patients a synthetic stand-in for a natural lubricant when the body stops making enough on its own.
The human trials in Australia will test the synthetic lubricin to treat osteoarthritis in the knees, and trials in Canada will test it as a remedy for dry eye disease. If successful, the innovations could become viable treatment options for sufferers.
Read more: